Skip to main content
SpringerLink
Log in

Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Upper extremity deep vein thrombosis (UEDVT) may occur without inciting factor or may be secondary to malignancy, surgery, trauma, central venous catheter or related to thoracic outlet syndrome (TOS). International guidelines recommend anticoagulant treatment for at least three months, in particular the use of vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). No data on extended anticoagulant therapy and reduced dose of DOACs have been reported in patients affected by UEDVT with persistent thrombotic risk (active cancer, major congenital thrombophilia) or without affected vein recanalization. In our retrospective observational study, including 43 patients, we treated secondary UEDVT with DOACs. In the acute phase of thrombosis (median time of 4 months), we used therapeutic dose of DOACs; the 32 patients with permanent thrombotic risk factors or without recanalization of the UEDVT were shifted to low-dose DOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg daily). During therapy with full-dose DOACs, 1 patient presented recurrence of thrombosis; no thromboembolic events were observed during treatment with low-dose DOACs. During full-dose treatment, 3 patients presented minor hemorrhagic complications; no hemorrhagic events were observed during DOACs at low dose. We think our preliminary data could support the indication to extend the anticoagulation with dose reduction of DOACs in patients affected by UEDVT and no-transient thrombotic risk. These data should be confirmed in randomized controlled prospective study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Isma N, Svensson PJ, Gottaster A, Lindblad B (2010) Upper extremity deep venous thrombosis in the population-based Malmö Thrombophilia Study (MATS): epidemiology, risk factors, recurrence risk, and mortality. Thromb Res 125(6):e335–e338

    Article  CAS  PubMed  Google Scholar 

  2. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ (2004) Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 110:1605–1611

    Article  PubMed  Google Scholar 

  3. Muñoz FJ, Mismetti P, Poggio R et al (2008) Clinical outcome of patients with upperextremity deep vein thrombosis: results from the RIETE Registry. Chest 133:143–148

    Article  PubMed  Google Scholar 

  4. Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo TC (2010) Pulmonary embolism from upper extremity deep vein thrombosis and the role of superior vena cava filters: a review of the literature. J Vasc Interv Radiol 21:779–787

    Article  PubMed  Google Scholar 

  5. Spencer FA, Emery C, Lessard D, Goldberg RJ (2007) Upper extremity deep vein thrombosis: a community-based perspective. Am J Med 120:678–684

    Article  PubMed  PubMed Central  Google Scholar 

  6. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ (2004) Deep vein thrombosis (DVT) FREE Steering Committee. Upper extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 110:1605–1611

    Article  PubMed  Google Scholar 

  7. Kucher N (2011) Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med. Mar 3;364(9):861-9. doi: https://doi.org/10.1056/NEJMcp1008740. PMID: 21366477

  8. Illig KA, Doyle AJ (2010) A comprehensive review of Paget-Schroetter syndrome. J Vasc Surg. 2010 Jun;51(6):1538-47. doi: https://doi.org/10.1016/j.jvs.2009.12.022. PMID: 20304578

  9. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Farjat AE, Zaghdoun A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Darius H, Kakkar AK (2019) Upper extremity DVT versus lower extremity DVT: perspectives from the GARFIELD-VTE registry. Thromb Haemost 119(8):1365–1372

    Article  PubMed  Google Scholar 

  10. Elman EE, Kahn SR (2006) The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 117:609–614

    Article  CAS  PubMed  Google Scholar 

  11. Bleker SM, van Es N, Kleinjan A et al (2016) Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis. J Thromb Haemost 14(5):973–981

    Article  CAS  PubMed  Google Scholar 

  12. Flinterman LE, Van Der Meer FJM, Rosendaal FR, Doggen CJM (2008) Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 6(08):1262–1266

    Article  CAS  PubMed  Google Scholar 

  13. Thiyagarajah K, Ellingwood L, Endres K et al (2019) Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: a systematic review and meta-analysis. Thromb Res 174:34–39

    Article  CAS  PubMed  Google Scholar 

  14. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712–1723

    Article  CAS  PubMed  Google Scholar 

  15. Lyman GH, Carrier M, Ay C et al (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Dec;160(6):e545-e608. doi: https://doi.org/10.1016/j.chest.2021.07.055

  17. Moik F, Colling M, Mahé I, Jara-Palomares L, Pabinger I, Ay C (2022) Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review. J Thromb Haemost 20(3):619–634. https://doi.org/10.1111/jth.15599

    Article  PubMed  Google Scholar 

  18. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694

    Article  CAS  PubMed  Google Scholar 

  19. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis. 9th ed: american college of chest Physicians evidence based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494S

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Valeriani E, Di Nisio M, Porceddu E, Agostini F, Pola R, Spoto S, Donadini MP, Ageno W, Porfidia A (2022) Anticoagulant treatment for upper extremity deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost 20(3):661–670. https://doi.org/10.1111/jth.15614

    Article  CAS  PubMed  Google Scholar 

  21. Davies GA, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M, Corpuz R, Kovacs MJ (2018) A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (catheter 2). Thromb Res 2018 Feb 162:88–92. https://doi.org/10.1016/j.thromres.2017.04.003

    Article  CAS  Google Scholar 

  22. Montiel FS, Ghazvinian R, Gottsäter A, Elf J (2017) Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J. 2017 Oct 3;15:26. doi: https://doi.org/10.1186/s12959-017-0149-x. PMID: 29026346

  23. Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M (2019) Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: A Systematic Review and Meta-Analysis. J. Thromb. Haemost. JTH. 2019;17:645–656. doi: https://doi.org/10.1111/jth.14398

  24. Larsen TL, Garresori H, Brekke J et al (2022) Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. J Thromb Haemost 20(5):1166–1181. https://doi.org/10.1111/jth.15666

    Article  CAS  PubMed  Google Scholar 

  25. Vedovati MC, Tratar G, Mavri A, Mazzetti M, Salazar Rosa V, Pierpaoli L, Cotugno M, Agnelli G, Becattini C (2021) Upper extremities deep vein thrombosis treated with oral direct anticoagulants: a prospective cohort study. Int J Cardiol 2021 Sep 15:339:158–163. https://doi.org/10.1016/j.ijcard.2021.07.005

    Article  Google Scholar 

Download references

Funding

The authors did not receive support from any organization for the submitted paper. No specific grant from any funding agency in the public commercial or not-for-profit sector was received for this research.

Author information

Authors and Affiliations

  1. Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Via Benevento 6, Rome, 00161, Italy

    S. Ligia, P. Musiu, A. Serrao, C. Santoro, A. Taglietti, M. Capriata, A. Faccini, M. C. Molinari, E. Baldacci & Antonio Chistolini

Authors
  1. S. Ligia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Musiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Serrao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Taglietti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Capriata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Faccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. C. Molinari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Baldacci
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Antonio Chistolini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Chistolini.

Ethics declarations

Ethics approval and consent to participate

Compliance with Italian ethical standards; informed consent to the use of patients’ data was obtained from all individual participants included in the study. Since this was a retrospective analysis of clinical charts, ethical approval was not needed.

Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ligia, S., Musiu, P., Serrao, A. et al. Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis. J Thromb Thrombolysis 56, 323–326 (2023). https://doi.org/10.1007/s11239-023-02842-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-023-02842-6

Keywords

Search

Navigation